References
- Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 4\(Suppl. 3), S265—S272 (2002).
- Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum. 42,415-420 (1999).
- Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ac/Hoc Committee on Clinical Guidelines. Arthritis Rheum. 39, 713–722 (1996).
- Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health 3,243–252 (2000).
- Callahan LE The burden of rheumatoid arthritis: facts and figures. 1. Rheumatol 53 (Suppl.), 8–12 (1998).
- Genovese MC, Bathon JM, Martin RVV et al Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46,1443–1450 (2002).
- Maini R, St Clair EW, Breedveld F et al Infliximab (chimeric antitumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 354, 1932–1939 (1999).
- ••Key clinical trial report for infliximab plusmethotrexate
- Cohen S, Hurd E, Cush J et al Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a 24-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614–624 (2002).
- •Key clinical trial report for anakinra plus MTX.
- Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Pc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. Merl 340,253–259 (1999).
- KLareskog L, van der HD, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004).
- •Key clinical trial report for etanercept and for etanercept plus MTX.
- Chiou CF, Weisman M, Sherboume CD et al Measuring preference weights for American College of Rheumatology response criteria for patients with rheumatoid arthritis. Annual European Congress of Rheumatology EULAR, Berlin, Germany, June (2004).
- •Key reference for preference weights for health states.
- Abbott Laboratories. HumiraTm (adalimumab) Prescribing Information. Package Insert. (2003).
- Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human antitumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48,35–45 (2003).
- •Key clinical trial report for adalimumab plus MTX.
- Bresnihan B, Alvaro-Gracia JM, Cobby M et al Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196–2204 (1998).
- •Key clinical trial report for anakinra.
- Moreland LW, Schiff MH, Baumgartner SW et al Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130,478–486 (1999).
- Lipsky PE, van der Heijde DM, St Clair EW et al Infliximab and methotrexate in the treatment of rheumatoid arthritis. AntiTumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl. I Med. 343,1594–1602(2000).
- Average Wholesale Price. First DataBank. (2003).
- Anonymous. 2003 CPT Expert Second Edition. Ingenix Publishing Group, UT, USA (2002).
- Ware JE Jr, Sherbourne CD. The MOS 36- item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care. 30,473-483 (1992).
- Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. .1. Rheumatol 9,789–793 (1982).
- Wong AL, Wong WK, Harker J et al Patient self-report tender and swollen joint counts in early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. j Rheumatol 26, 2551–2561 (1999).
- Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 42, 326–335 (2003).
- Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am. Med 113,400–408 (2002).
- Choi HK, Seeger JD, Kuntz KM. A cost- effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheumatism. 43,2316–2327 (2000).
- Amgen. Anakinra (Kinereta) Prescribing Information. (2003).
- Burmester GR, van de Putte BA, Rau R, Breedveld E Long-term effectiveness and safety of adalimumab (D2E7) monotherapy in patients with DMARD-refractory rheumatoid arthritis. Paper presented at 66th Annual Scientific Meeting of the American College of Rheumatology LA, USA (2002).
- Centocor. Infliximab (Remicadee) Prescribing Information. Package Insert. (2003). Websites
Websites
- Lipsky P. Rheumatoid Arthritis. In: Harrison's Text Book of Medicine Online. http://harrisons.accessmedicine.com/ server-java/Arknoidiamed/harrisonsi co_chaptersich312/ch312_p01.html. (Accessed May 2004)
- National Heritage Insurance Company. 2003 Physician Fee Schedule. Centers for Medicare and Medicaid Services http://cms.hhs.gov/providersipufdownload (Accessed May 2004)
- The Medstat Diagnosis Related Group (DRG) Guide. The Medstat Group, Inc. www.medstat.com (Accessed May 2004)